Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
1.
Rev Med Interne ; 2024 Feb 07.
Article Fr | MEDLINE | ID: mdl-38331591

INTRODUCTION: The "Printemps de la Médecine Interne" are training days for Francophone internists. The clinical cases presented during these days are complex. This study aims to evaluate the diagnostic capabilities of non-specialized artificial intelligence (language models) ChatGPT-4 and Bard by confronting them with the puzzles of the "Printemps de la Médecine Interne". METHOD: Clinical cases from the "Printemps de la Médecine Interne" 2021 and 2022 were submitted to two language models: ChatGPT-4 and Bard. In case of a wrong answer, a second attempt was offered. We then compared the responses of human internist experts to those of artificial intelligence. RESULTS: Of the 12 clinical cases submitted, human internist experts diagnosed nine, ChatGPT-4 diagnosed three, and Bard diagnosed one. One of the cases solved by ChatGPT-4 was not solved by the internist expert. The artificial intelligence had a response time of a few seconds. CONCLUSIONS: Currently, the diagnostic skills of ChatGPT-4 and Bard are inferior to those of human experts in solving complex clinical cases but are very promising. Recently made available to the general public, they already have impressive capabilities, questioning the role of the diagnostic physician. It would be advisable to adapt the rules or subjects of future "Printemps de la Médecine Interne" so that they are not solved by a public language model.

2.
Rev Med Interne ; 41(6): 413-417, 2020 Jun.
Article Fr | MEDLINE | ID: mdl-32113636

INTRODUCTION: Erdheim-Chester disease (ECD) is a rare multisystemic disease characterised by an infiltration of various organs by CD68+ CD1a- histiocytes. The clinical and radiological presentation is very variable. CASE REPORT: We report the case of a 71-year-old woman with ECD which was revealed by neurological and cutaneous manifestations. The diagnosis was confirmed by skin biopsy and the BRAFV600E mutation was identified in skin tissue, leading to the use of combined therapy targeting the RAS-RAF-ERK-MEK pathway. This therapy allowed an improvement of cutaneous manifestations but neurological manifestations lead to death, underlying their notable severity. CONCLUSION: Our case report shows the persistent diagnostic difficulty of the ECD and the particular gravity of neurologic involvement.


Erdheim-Chester Disease/complications , Erdheim-Chester Disease/drug therapy , Molecular Targeted Therapy , Nervous System Diseases/drug therapy , Nervous System Diseases/etiology , Protein Kinase Inhibitors/administration & dosage , Aged , Azetidines/administration & dosage , Drug Therapy, Combination , Erdheim-Chester Disease/diagnosis , Female , Humans , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Molecular Targeted Therapy/methods , Nervous System Diseases/diagnosis , Piperidines/administration & dosage , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Rare Diseases , Skin Diseases/diagnosis , Skin Diseases/etiology , Skin Diseases/pathology , Skin Diseases/therapy , Vemurafenib/administration & dosage
3.
Rev Med Interne ; 38(4): 228-234, 2017 Apr.
Article Fr | MEDLINE | ID: mdl-27876175

INTRODUCTION: Anti-3-hydroxy-3-méthylglutaryl-coenzyme A reductase antibody-associated necrotizing autoimmune myopathy has been recently described (2011). This myopathy is distinct from statin toxic myopathy. Our objective is to report on the clinical and para-clinical characteristics of this myopathy and to show the difficulties of therapeutic care. CASE REPORTS: We describe 4 cases of patients followed-up in Brittany, France. All data have been analyzed retrospectively. The mean age of our patients was 59.5 years, with a sex ratio of 1. The clinical presentation was homogeneous, with a subacute painful proximal and symmetrical weakness, without extra-muscular involvement. Other presentations have been described (including pseudo-dystrophic presentation). All patients had a previous statin medication (mean duration of 3.75 years) although this criteria is not a requisite. All patients had high levels of creatine kinase and abnormal electromyographic examination. The pathological pattern on muscular biopsy was a necrotizing myopathy without significant inflammatory cells infiltration. Cardio-respiratory function was normal and no associated neoplasia was found. Over the follow-up, we observed a marked corticosteroid-dependence, not improved by immunosuppressive drugs (azathioprine and methotrexate). The benefit of intravenous immunoglobulin was clear with, sometimes, prolonged responses. CONCLUSION: An early diagnosis of this myopathy is necessary in order to introduce an immunotherapy associated with a close monitoring. The therapeutic strategy (within which the stead of intravenous immunoglobulin seems increased) remains to be defined and long-term prospective studies are thus needed.


Autoantibodies/adverse effects , Autoimmune Diseases/diagnosis , Hydroxymethylglutaryl CoA Reductases/immunology , Muscle, Skeletal/pathology , Muscular Diseases/diagnosis , Aged , Autoantibodies/blood , Autoimmune Diseases/blood , Autoimmune Diseases/complications , Autoimmune Diseases/immunology , Female , France , Humans , Male , Middle Aged , Muscular Diseases/complications , Muscular Diseases/immunology , Muscular Diseases/pathology , Necrosis/complications , Retrospective Studies
4.
Med Mal Infect ; 44(7): 327-30, 2014 Jul.
Article En | MEDLINE | ID: mdl-25022891

OBJECTIVES: We evaluated the benefit/risk ratio of outpatient parenteral antimicrobial therapy (OPAT) in infective endocarditis (IE). METHOD: We performed an observational retrospective study of definite IE (Duke criteria) treated in an infectious diseases unit in 2012. We compared patients having completed the treatment in hospital (H), and those deemed sufficiently stable, and with adequate home environment, for OPAT. The costs were estimated through hospital bills, and, for OPAT, through the costs of drugs and their administration (material, staff), transportation, and outpatient visits. RESULTS: Eighteen out of 39 consecutive patients presenting with IE received OPAT, with a mean hospital stay of 23.5days (vs 34.7days for H group, P=0.014). No severe adverse event related to OPAT was reported. The global saving was estimated at 267,307euros, or 14,850euros per patient. CONCLUSIONS: OPAT in selected patients presenting with IE seems effective, safe, and reduces costs by approximately 15,000euros per patient.


Ambulatory Care/economics , Anti-Infective Agents/economics , Cost of Illness , Endocarditis/drug therapy , Home Care Services/economics , Adolescent , Adult , Aged , Anti-Infective Agents/administration & dosage , Central Venous Catheters , Combined Modality Therapy , Cost Savings , Cost-Benefit Analysis , Drug Costs/statistics & numerical data , Endocarditis/economics , Endocarditis/surgery , Female , France , Home Care Services/organization & administration , Hospital Costs/statistics & numerical data , Hospitalization/economics , Humans , Infusion Pumps, Implantable , Infusions, Intravenous , Injections , Male , Middle Aged , Outpatient Clinics, Hospital/economics , Quality of Life , Retrospective Studies , Transportation/economics , Young Adult
5.
Rev Med Interne ; 29(12): 1043-5, 2008 Dec.
Article Fr | MEDLINE | ID: mdl-18572283

Giant cell arteritis, a large-sized vessel vasculitis, may be associated with musculoskeletal proximal (polymyalgia rheumatica) or distal manifestations. A 68-year-old woman, who had inflammatory pelvic girdle pain, was diagnosed with giant cell arteritis and was successfully treated with corticosteroids. The magnetic resonance imaging and ultrasonography revealed a bilateral bursitis and pelvic girdle enthesopathy. Bursitis is the main anatomic lesion occurring in polymyalgia rheumatica and can be underlined by ultrasonography.


Bursitis , Giant Cell Arteritis , Hip Joint , Polymyalgia Rheumatica , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Aged , Biopsy , Bursitis/diagnosis , Bursitis/diagnostic imaging , Female , Giant Cell Arteritis/diagnosis , Giant Cell Arteritis/drug therapy , Giant Cell Arteritis/pathology , Humans , Magnetic Resonance Imaging , Polymyalgia Rheumatica/diagnosis , Temporal Arteries/pathology , Treatment Outcome , Ultrasonography
...